Ziresovir
Small moleculeexperimental
Clinical trial activity
11 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Oct 1, 2014 (NCT02297594)
Timeline
Indications
Mechanism of action
- Fusion glycoprotein F0INHIBITOR
Fusion glycoprotein F0 inhibitor
- RSV F-proteinINHIBITOR
RSV F-protein inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc2nc(N3CCS(=O)(=O)c4ccccc4C3)nc(NCC3(N)COC3)c2c1- Mol. weight
- 439.54 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4468815 ↗
Also known as
- ak0529
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06591845 | Phase 1 | Sep 15, 2024 | Ark Biosciences Inc., California Clinical Trials |
| NCT06775405 | Phase 3 | Feb 29, 2024 | Ark Biosciences Inc. |
| NCT06942299 | Phase 2 | Jul 20, 2023 | Ark Biosciences Inc. |
| NCT04788017 | Phase 1 | Apr 5, 2021 | Ark Biosciences Inc. |
| NCT04231968 | Phase 3 | Feb 29, 2020 | Ark Biosciences Inc. |
| NCT03699202 | Phase 2 | Mar 29, 2019 | Ark Biosciences Inc. |
| NCT03400995 | Phase 1 | Jan 5, 2018 | Ark Biosciences Inc. |
| NCT03322800 | Phase 1 | Oct 23, 2017 | Ark Biosciences Inc. |
| NCT02654171 | Phase 2 | May 27, 2016 | Ark Biosciences Inc. |
| NCT02460016 | Phase 1 | Sep 1, 2015 | Ark Biosciences Inc. |
| NCT02297594 | Phase 1 | Oct 1, 2014 | Ark Biosciences Inc., Q-Pharm |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ark Biosciences Inc. | For profit | 11 | 11 | 3 | 2014 |
| California Clinical Trials | For profit | 1 | 0 | 1 | 2024 |
| Q-Pharm | For profit | 1 | 0 | 1 | 2014 |
3 organizations
Page 1 / 1